TABLE 3

Nonsynonymous mutations in pncA and alr improve diagnosis of resistance to pyrazinamide and cycloserine, respectivelya

DrugGeneMutationFrequencyPPVSensitivitySpecificity
PyrazinamideAny19111
pncALOF310.161
D8N110.051
Q10R110.051
D12A110.051
V21A110.051
D49G/Y510.261
H57D110.051
W68G/R510.261
L151W110.051
Cycloserine150.730.330.93
alrL89R150.730.330.93
  • a Isolates were included only if they had both phenotypic and genotypic resistance predictions. For each mutation, we show the frequency of the mutation in the data set, positive predictive value (PPV), sensitivity, and specificity for predicting phenotypic resistance. Mutations are either listed as specific changes or as any loss-of-function (LOF) mutation, including nonsense mutations and frameshifts.